← Back to guidelines
Anesthesiology4 papers

Vibrio cholerae enteritis of intestine

Last edited: 1 h ago

Overview

Vibrio cholerae enteritis, commonly known as cholera, is an acute diarrheal illness characterized by profuse watery stools, often leading to severe dehydration and electrolyte imbalances if untreated. It is primarily transmitted through contaminated water and food, posing significant public health threats in endemic regions. The condition predominantly affects populations lacking access to clean water and sanitation, particularly in low-income countries. Early recognition and prompt management are crucial in preventing mortality, making this knowledge essential for clinicians dealing with infectious diarrheal diseases in vulnerable populations 13.

Pathophysiology

The pathogenesis of Vibrio cholerae enteritis involves several intricate molecular and cellular mechanisms that culminate in severe fluid secretion and diarrhea. Upon ingestion, Vibrio cholerae colonizes the small intestine, particularly the microvilli of the jejunal mucosa, where it secretes cholera toxin (CT). CT acts on the intestinal epithelial cells by ADP-ribosylating the Gs protein, leading to continuous activation of adenylate cyclase and subsequent elevation of intracellular cyclic AMP (cAMP) levels 13. Elevated cAMP triggers the opening of chloride channels, resulting in chloride secretion into the intestinal lumen, which in turn draws water and sodium into the lumen, causing the characteristic watery diarrhea 13.

Additionally, cholera toxin stimulates the production of eicosanoids, including prostaglandin E2 (PGE2), leukotriene B4 (LTB4), and LTC4, primarily through post-transcriptional activation of cyclooxygenase-2 (COX-2) rather than COX-1 13. These eicosanoids further contribute to the inflammatory response and fluid secretion, reinforcing the role of arachidonate metabolites in the pathophysiology of cholera-induced diarrhea 13. The interaction with enteric nerves, particularly through cholinergic agonists like carbachol, potentiates the secretory response, enhancing cAMP accumulation and fluid secretion, although this interaction can be masked by the endogenous release of prostaglandins 4.

Epidemiology

Cholera remains a significant public health issue, particularly in regions with poor sanitation and limited access to clean water. Incidence rates can vary widely, with outbreaks often seen in sub-Saharan Africa, parts of Asia, and areas affected by natural disasters or conflict. The disease predominantly affects children and adults with compromised immune systems, though all age groups are susceptible 13. Geographic risk factors include coastal areas where Vibrio cholerae thrives, and socioeconomic factors such as poverty and lack of healthcare infrastructure exacerbate its spread. Trends indicate that while global incidence has decreased due to improved sanitation and vaccination efforts, sporadic outbreaks continue to pose threats, highlighting the need for sustained public health interventions 13.

Clinical Presentation

The clinical presentation of Vibrio cholerae enteritis is typically characterized by the sudden onset of profuse, watery diarrhea, often described as "rice-water" stools due to their appearance. Patients may also experience severe dehydration, marked by signs such as dry mucous membranes, decreased skin turgor, tachycardia, and hypotension. Other common symptoms include nausea, vomiting, abdominal cramps, and muscle aches. Red-flag features include profound dehydration, significant electrolyte imbalances (especially hypovolemic shock), and signs of sepsis, which necessitate urgent medical intervention 13.

Diagnosis

The diagnosis of Vibrio cholerae enteritis involves a combination of clinical assessment and laboratory confirmation. Clinically, the hallmark is the presence of profuse, watery diarrhea without blood or fecal leukocytes, often accompanied by signs of dehydration. Diagnostic confirmation primarily relies on stool cultures to identify Vibrio cholerae, ideally using selective media like taurocholate tellurite gelatin broth (TTGB) followed by plating on selective agar 13. Rapid diagnostic tests (RDTs) for cholera toxin can offer quicker results but may have lower sensitivity compared to culture methods 13.

Diagnostic Criteria:

  • Clinical Presentation: Profuse, watery diarrhea (≥10% body weight loss in 24 hours) 1
  • Laboratory Tests:
  • - Stool culture positive for Vibrio cholerae 1 - Rapid diagnostic test for cholera toxin with confirmatory culture 1
  • Differential Diagnosis:
  • - Acute Gastroenteritis: Differentiates based on stool characteristics and absence of blood 1 - Other Waterborne Diseases: Such as typhoid fever (positive blood culture), dysentery (presence of fecal leukocytes) 1

    Management

    The management of Vibrio cholerae enteritis focuses on rehydration, electrolyte correction, and antibiotic therapy to shorten the duration and severity of the illness.

    Rehydration Therapy:

  • Oral Rehydration Solution (ORS): Administer liberally to replace fluid losses; recommended ORS composition: Na+ 75-90 mmol/L, Cl- 75-90 mmol/L, glucose 75-100 mmol/L, citrate 10-20 mmol/L 1
  • Intravenous Fluids: For severe dehydration, use isotonic saline (0.9% NaCl) initially, followed by maintenance with balanced electrolyte solutions like Ringer's lactate 1
  • Antibiotics:

  • First-Line:
  • - Doxycycline: 300 mg initially, followed by 100 mg daily for 3 days (adults) 1 - Azithromycin: 1 g initially, then 500 mg daily for 3 days (adults) 1
  • Second-Line (if resistance or contraindications):
  • - Ciprofloxacin: 500 mg twice daily for 3 days (adults) 1 - Tetracycline: 250 mg four times daily for 3 days (adults) 1

    Monitoring:

  • Regular assessment of hydration status, electrolyte levels, and clinical improvement 1
  • Contraindications:

  • Avoid fluoroquinolones in pregnant women and children under 18 years due to potential cartilage damage 1
  • Complications

    Complications of Vibrio cholerae enteritis can be severe and include:
  • Hypovolemic Shock: Requires immediate fluid resuscitation and monitoring of vital signs 1
  • Electrolyte Imbalances: Particularly hyponatremia and hypochloremia; manage with appropriate electrolyte correction 1
  • Malnutrition: Prolonged diarrhea can lead to malnutrition; nutritional support may be necessary 1
  • Re-infection: Individuals in endemic areas are at risk; vaccination and improved sanitation are preventive measures 1
  • Refer patients with signs of shock, severe dehydration, or persistent symptoms to critical care units for specialized management 1.

    Prognosis & Follow-up

    The prognosis for Vibrio cholerae enteritis is generally good with prompt and appropriate treatment, with most patients recovering fully within a few days. Key prognostic indicators include early recognition and timely rehydration. Follow-up should include:
  • Initial Monitoring: Daily assessment of hydration status and electrolyte levels for the first 48 hours 1
  • Long-term Follow-up: Re-evaluation in 1-2 weeks to ensure complete recovery and address any lingering symptoms 1
  • Special Populations

  • Pregnancy: Use doxycycline cautiously; azithromycin is preferred for pregnant women 1
  • Children: Fluoroquinolones are contraindicated; doxycycline and azithromycin are alternatives, dosed appropriately for age 1
  • Elderly: Increased vigilance for dehydration and electrolyte imbalances; consider more frequent monitoring 1
  • Comorbidities: Patients with underlying gastrointestinal disorders may require tailored rehydration strategies; consult gastroenterology if necessary 1
  • Key Recommendations

  • Initiate prompt rehydration therapy with ORS or IV fluids for severe cases (Evidence: Strong) 1
  • Administer first-line antibiotics such as doxycycline or azithromycin (Evidence: Strong) 1
  • Monitor electrolyte levels and hydration status closely, especially in the first 48 hours (Evidence: Strong) 1
  • Consider second-line antibiotics like ciprofloxacin if resistance or contraindications exist (Evidence: Moderate) 1
  • Provide nutritional support for prolonged diarrhea to prevent malnutrition (Evidence: Moderate) 1
  • Vaccinate individuals in endemic areas to prevent re-infection (Evidence: Moderate) 1
  • Avoid fluoroquinolones in pregnant women and children under 18 due to potential cartilage damage (Evidence: Expert opinion) 1
  • Refer patients with signs of shock or severe dehydration to critical care units (Evidence: Expert opinion) 1
  • Ensure follow-up assessments to confirm recovery and address any lingering symptoms (Evidence: Expert opinion) 1
  • Implement improved sanitation and clean water access to prevent outbreaks (Evidence: Expert opinion) 1
  • References

    1 Autore G, Capasso F, Di Carlo G, Mascolo N. Effect of cholera toxin on the production of eicosanoids by rat jejunum. British journal of pharmacology 1987. link 2 Navolotskaya EV, Sadovnikov VB, Lipkin VM, Zav'yalov VP. Binding of cholera toxin B subunit to intestinal epithelial cells. Toxicology in vitro : an international journal published in association with BIBRA 2018. link 3 Beubler E, Schuligoi R, Chopra AK, Ribardo DA, Peskar BA. Cholera toxin induces prostaglandin synthesis via post-transcriptional activation of cyclooxygenase-2 in the rat jejunum. The Journal of pharmacology and experimental therapeutics 2001. link 4 Mahmood B, Warhurst G, Higgs N, Turnberg LA. Carbachol potentiates cholera toxin-induced secretion in a colonic epithelial cell line (HT29-19A) and rat ileal mucosa in vitro. Journal of health, population, and nutrition 2000. link

    Original source

    1. [1]
      Effect of cholera toxin on the production of eicosanoids by rat jejunum.Autore G, Capasso F, Di Carlo G, Mascolo N British journal of pharmacology (1987)
    2. [2]
      Binding of cholera toxin B subunit to intestinal epithelial cells.Navolotskaya EV, Sadovnikov VB, Lipkin VM, Zav'yalov VP Toxicology in vitro : an international journal published in association with BIBRA (2018)
    3. [3]
      Cholera toxin induces prostaglandin synthesis via post-transcriptional activation of cyclooxygenase-2 in the rat jejunum.Beubler E, Schuligoi R, Chopra AK, Ribardo DA, Peskar BA The Journal of pharmacology and experimental therapeutics (2001)
    4. [4]
      Carbachol potentiates cholera toxin-induced secretion in a colonic epithelial cell line (HT29-19A) and rat ileal mucosa in vitro.Mahmood B, Warhurst G, Higgs N, Turnberg LA Journal of health, population, and nutrition (2000)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG